PMGC Holdings Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Graydon Bensler
- Full Time Employees
- 34
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 120 Newport Center Drive Newport Beach CA United States of America 92660
- IPO Date
- Nov 21, 2023
- CIK
- 0001840563
- Website
- pmgcholdings.com
- Similar Companies
- Business
- PMGC Holdings Inc. operates as a diversified holding company focused on acquiring, managing, and growing cash-flowing businesses primarily in the manufacturing, biopharmaceutical, research, and investment sectors. The company, through its wholly owned subsidiaries, offers biopharmaceutical development including the lead asset EL-22, a first-in-class engineered probiotic therapy designed to preserve muscle mass during weight loss treatments such as GLP-1 receptor agonists; medical scientific research and development activities via PMGC Research Inc.; multi-strategy investment, lending, and portfolio management through PMGC Capital LLC; custom IT packaging solutions for electronics, data centers, and technology manufacturers via Pacific Sun Packaging Inc.; and precision CNC machining, aerospace, and defense manufacturing services through AGA Precision Systems LLC. PMGC Holdings maintains operations in the United States, targeting commercial, industrial, and healthcare customers with scalable, compliant products and services. Incorporated in 2020 and headquartered in Newport Beach, California, the company was formerly known as Elevai Labs Inc. and underwent a strategic reorganization and name change in December 2024. Recent developments include the sale of its Elevai Skincare subsidiary to Carmell Corporation in January 2025 for immediate financial benefit and future royalties; completion of the acquisition of Pacific Sun Packaging Inc. in July 2025 for $1.148 million plus earnout to enhance exposure to semiconductor and AI infrastructure; acquisition of AGA Precision Systems LLC in July 2025 and subsequent purchase of Indarg Engineering Inc. in Q4 2025 to expand aerospace and defense capabilities; partnerships such as with Yuva Biosciences for AI-powered therapies and Modulant Biosciences for animal model studies on EL-22; positive FDA feedback supporting an IND submission for Phase 2 trials of EL-22; new US patent filings for EL-22 and EL-32 programs; multiple financing activities including $8.0 million public offering in 2024, $1.9 million and $1.67 million warrant inducements in 2025, and a $1.48 million registered direct offering; and reverse stock splits in March and August 2025 to maintain Nasdaq listing compliance.
NorthStrive Defense Tech Executes Definitive Exclusive License Agreement with Florida State University Research Foundation for Multi-Domain Drone Payload Technology Across Defense, Aerospace and Maritime Applications
NorthStrive Defense Tech Executes Definitive Exclusive License Agreement with Florida State University Research Foundation for Multi-Domain Drone Payload Technology Across Defense, Aerospace and Maritime Applications
NorthStrive Biosciences to Advance EL-22 Manufacturing Characterization with Quantitative FACS Analysis of Latent Myostatin Antigen Expression
PMGC Holdings Inc. Announces Merger of AGA Precision Systems into A&B Aerospace
Wall Street is Watching These Biotechs
NorthStrive Biosciences Announces Positive Results from Phase III of AI-Driven Drug Discovery Program with Yuva Biosciences
NorthStrive Biosciences Files Two New U.S. Patent Applications Targeting Muscle Preservation in GLP-1 and Next-Generation Obesity Treatment Markets
PMGC Holdings Highlights Advanced Precision Manufacturing Capabilities Supporting Space Exploration Supply Chains
NorthStrive Defense Tech Executes Binding Agreement to Acquire Exclusive License to Patented Multi-Domain Drone Payload Technology for Defense, Aerospace and Maritime Applications
PMGC Holdings Signs Non-Binding Letter of Intent to Acquire Majority Stake in U.S.-Based Precision Machining Manufacturing Company Serving Aerospace, Space, Defense, and Semiconductor Markets
GB Capital Ltd. Co-Advises on the Acquisition of A&B Aerospace Inc.
PMGC Holdings Inc. [NASDAQ: ELAB] Reports Q1 2026 Results and Files Form 10-Q; Total Assets Reach Over $26.0 Million, Up 102% from Year-End 2025 and 193% Year-over-Year
PMGC Holdings (NASDAQ: ELAB) Acquires A&B Aerospace, Inc.
UPDATED: NorthStrive Biosciences Files New U.S. Patent Application Covering EL-22 Formulations and Dosing for Treatment of Muscle-Wasting Conditions related to GLP-1 Use, Sarcopenia, Muscle Disuse Atrophy, and Certain Neurological Disorders
NorthStrive Biosciences Files New U.S. Patent Application for EL-22 Targeting Muscle Preservation in Humans
NorthStrive Biosciences Files New U.S. Patent Application for EL-22 Targeting Muscle Preservation in Humans
NorthStrive Defense Tech Acquires Patented GPS-Denied Autonomous Drone Navigation Technology Option, Built for Defense and Counter-Unmanned Aircraft Systems
Univest Securities, LLC Announces a $40 Million Equity Line Facility for its Client PMGC Holdings, Inc. (NASDAQ: ELAB)
SVM Machining, Inc. Signs Long-Term Agreement to Supply Mission-Critical Aerospace and Defense Components to Turbo-Jet Products Co., Inc.
PMGC Holdings, Inc. (Nasdaq: ELAB) Secures $40 Million Equity Purchase Facility Agreement: Announces Ability To Accelerate M&A Strategy Currently Focused on Acquiring Aerospace and Defense Manufacturing Companies